Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
|Videos|November 9, 2019
Timothy Ray Brown: HIV Cure Cheerleader
Author(s)Contagion® Editorial Staff
Timothy Ray Brown is the first person to ever be cured of HIV. He discusses his decision to no longer remain anonymous and why he shares his story with the world.
Advertisement
Segment Description: At
Interview transcript: (modified slightly for readability)
Leading up to 2010, after my story broke in the New England Journal of Medicine, and then started becoming an important story, I decided I did not really want to be the “Berlin Patient” anymore. I wanted to have people know me by my name and so and I decided that I couldn't be the only person in the world cured of HIV. I was at that point, I didn't want that anymore. I wanted more people to be cured—I wanted everyone with HIV to be cured. And, and so in order to do that, I had to release my name and my image to the public and, and since then, I've become kind of a cheerleader for HIV cure.
Advertisement
Related to this article
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Fungal-WHAT? Updates to the WHO Antifungal Pipeline
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5